NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD
Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 568 industry peers in the Biotechnology industry. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BIIB has a bad growth rate and is valued cheaply. With these ratings, BIIB could be worth investigating further for value investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.82% | ||
ROE | 9.76% | ||
ROIC | 9.92% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 26.35% | ||
PM (TTM) | 16.87% | ||
GM | 76.12% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.27 | ||
Debt/FCF | 2.5 | ||
Altman-Z | 2.61 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.35 | ||
Quick Ratio | 0.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 7.07 | ||
Fwd PE | 7.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 6.78 | ||
EV/EBITDA | 6.6 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
116.49
-2.12 (-1.79%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 7.07 | ||
Fwd PE | 7.24 | ||
P/S | 1.76 | ||
P/FCF | 6.78 | ||
P/OCF | 5.93 | ||
P/B | 1.02 | ||
P/tB | 31.23 | ||
EV/EBITDA | 6.6 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.82% | ||
ROE | 9.76% | ||
ROCE | 11.32% | ||
ROIC | 9.92% | ||
ROICexc | 11.09% | ||
ROICexgc | 56.18% | ||
OM | 26.35% | ||
PM (TTM) | 16.87% | ||
GM | 76.12% | ||
FCFM | 26% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.27 | ||
Debt/FCF | 2.5 | ||
Debt/EBITDA | 1.41 | ||
Cap/Depr | 53.45% | ||
Cap/Sales | 3.72% | ||
Interest Coverage | 10.39 | ||
Cash Conversion | 89.23% | ||
Profit Quality | 154.13% | ||
Current Ratio | 1.35 | ||
Quick Ratio | 0.9 | ||
Altman-Z | 2.61 |